Calliditas Therapeutics AB
NASDAQ:CALT

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
NASDAQ:CALT
Watchlist
Price: 40.0001 USD
Market Cap: 1.1B USD

Intrinsic Value

The intrinsic value of one CALT stock under the Base Case scenario is 135.0319 USD. Compared to the current market price of 40.0001 USD, Calliditas Therapeutics AB is Undervalued by 70%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CALT Intrinsic Value
135.0319 USD
Undervaluation 70%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Calliditas Therapeutics AB

What is Valuation History?
Compare CALT to

Fundamental Analysis

Calliditas Therapeutics AB
NASDAQ:CALT
SE
Pharmaceuticals
Market Cap
1.1B USD
IPO
Jun 29, 2018
SE
Pharmaceuticals
Market Cap
1.1B USD
IPO
Jun 29, 2018
Price
$false
EPS
krfalse
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CALTX?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Calliditas Therapeutics AB
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Calliditas Therapeutics AB

Current Assets 1.2B
Cash & Short-Term Investments 797.3m
Receivables 222.6m
Other Current Assets 134.6m
Non-Current Assets 592.7m
Long-Term Investments 27.2m
PP&E 59.4m
Intangibles 471.7m
Other Non-Current Assets 34.5m
Efficiency

Free Cash Flow Analysis
Calliditas Therapeutics AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Calliditas Therapeutics AB

Revenue
1.6B SEK
Cost of Revenue
-104.7m SEK
Gross Profit
1.5B SEK
Operating Expenses
-1.8B SEK
Operating Income
-353.1m SEK
Other Expenses
-127.2m SEK
Net Income
-480.4m SEK
Fundamental Scores

CALT Profitability Score
Profitability Due Diligence

Calliditas Therapeutics AB's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Gross Margin
Strong 3Y Average Gross Margin
Operating Margin is Increasing
25/100
Profitability
Score

Calliditas Therapeutics AB's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

CALT Solvency Score
Solvency Due Diligence

Calliditas Therapeutics AB's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
45/100
Solvency
Score

Calliditas Therapeutics AB's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CALT Price Targets Summary
Calliditas Therapeutics AB

There are no price targets for CALT.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Calliditas Therapeutics AB
does not pay dividends
Shareholder Yield

Current shareholder yield for CALTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CALT stock?

The intrinsic value of one CALT stock under the Base Case scenario is 135.0319 USD.

Is CALT stock undervalued or overvalued?

Compared to the current market price of 40.0001 USD, Calliditas Therapeutics AB is Undervalued by 70%.

Back to Top